Correction to: Cancer Immunology, Immunotherapy https://doi.org/10.1007/s00262-020-02554-3
The original version of this article unfortunately contained a mistake. The correct information is given below.
In abstract , the second and third sentences should read as
This study aimed to investigate the expression of VISTA and its association with clinicopathologic parameters as well as with the key immune markers including programmed cell death-1 (PD-1) and PD-1 ligand-1 (PD-L1) in invasive ductal carcinoma (IDC) of the breast.
Immunohistochemistry was used to detect VISTA, PD-1, PD-L1, and CD8 in tissue microarrays from 919 patients with IDC (N = 341 in the exploratory cohort and N = 578 in the validation cohort).
In section “Evaluation of immunostaining”, the fifth sentence of the second paragraph should read as
Luminal A was defined as ER + (≥ 1%) or PR + (≥ 1%), HER2–, and low Ki67(< 14%); luminal B was defined as ER + (or PR +) and HER2 + or high Ki67 (≥ 14%); HER2-enriched (HER2E) was defined as HER + , ER–, and PR–; and basal-like was defined as ER–, PR–, and HER2– with either EGFR + or CK5/6 + .
Author information
Authors and Affiliations
Corresponding authors
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Zong, L., Mo, S., Yu, S. et al. Correction to: Expression of the immune checkpoint VISTA in breast cancer. Cancer Immunol Immunother 69, 1447 (2020). https://doi.org/10.1007/s00262-020-02602-y
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00262-020-02602-y